Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ophthotech initiates enrollment in Phase I AMD trial
The Phase I trial will assess the safety and tolerability of E10030, an anti-PDGF aptamer, in combination with an anti-VEGF agent. E10030 is the first of three compounds
The Phase I trial will assess the safety and tolerability of E10030, an anti-PDGF aptamer, in combination with an anti-VEGF agent. E10030 is the first of three compounds
Wockhardt received approval from the FDA for marketing the tablets containing 250mg, 500mg and 600mg azithromycin, which is used for treating various kinds of infections. Azithromycin is the
This file has been accepted for review by the European Medicines Agency (EMEA). Clinical trials, involving more than 7,000 adult or elderly participants, evaluated the safety and ability
The planned research, which will be conducted as part of BG Medicine’s High Risk Plaque (HRP) Initiative, will apply BG Medicine’s proprietary proteomic and metabolomic discovery platform capabilities.
Each unit will be comprised of one common share of the company and one half of one share purchase warrant. Each whole warrant will entitle the holder to
Altor plans on initiating a multi-center, Phase II clinical study later in 2008, using the lead therapeutic antibody known as ALT-836 for the treatment of acute respiratory distress
The suit seeks injunctive relief and damages for infringement of three of the Andersen family of patents for transcatheter heart valve technology. These patents relate to valve prosthesis
While all of KRIBB’s technologies will be considered for transfer into ‘NuCo’, those having the greatest potential for contributing to the discovery of drugs that address unmet medical
The transaction was unanimously approved by the boards of directors of both companies and is anticipated to close during the second or third quarter of 2008, subject to
The product will be marketed under store brand labels and is comparable to Johnson & Johnson – Merck Consumer Pharmaceutical’s Pepcid Complete, an acid reducer plus antacid medication